Setting Up an NGS Sequencing Platform and Monitoring Molecular Markers of Anti-Malarial Drug Resistance in Djibouti

Overview

Journal Biology (Basel)

Publisher MDPI

Specialty Biology

Date 2024 Nov 27

PMID 39596860

Authors

Nasserdine Papa Mze

Houssein Yonis Arreh

Rahma Abdi Moussa

Mahdi Bachir Elmi

Mohamed Ahmed Waiss

Mohamed Migane Abdi

Hassan Ibrahim Robleh

Samatar Kayad Guelleh

Abdoul-Ilah Ahmed Abdi

Herve Bogreau

Leonardo K Basco

Bouh Abdi Khaireh

Affiliations

Soon will be listed here.

Abstract

Djibouti is confronted with malaria resurgence, with malaria having been occurring in epidemic proportions since a decade ago. The current epidemiology of drug-resistant is not well known. Molecular markers were analyzed by targeted sequencing in 79 clinical isolates collected in Djibouti city in 2023 using the Miseq Illumina platform newly installed in the country. The objective of the study was to analyze the key codons in these molecular markers associated with antimalarial drug resistance. The prevalence of the mutant CVIET haplotype (92%) associated with chloroquine resistance and mutant haplotypes (7.4% SGEA and 53.5% IRN, respectively) associated with sulfadoxine-pyrimethamine resistance was high. By contrast, haplotypes associated with amodiaquine (YYY) or lumefantrine (NFD) resistance were not observed in any of the isolates. Although the "Asian-type" mutations associated with artemisinin resistance were not observed, the "African-type" PfK13 substitution, R622I, was found in a single isolate (1.4%) for the first time in Djibouti. Our genotyping data suggest that most Djiboutian isolates are resistant to chloroquine and sulfadoxine-pyrimethamine but are sensitive to amodiaquine, lumefantrine, and artemisinin. Nonetheless, the presence of an isolate with the R622I PfK13 substitution is a warning signal that calls for a regular surveillance of molecular markers of antimalarial drug resistance.

References

Phyo A, Nkhoma S, Stepniewska K, Ashley E, Nair S, McGready R . Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012; 379(9830):1960-6. PMC: 3525980. DOI: 10.1016/S0140-6736(12)60484-X. View

Li H . New strategies to improve minimap2 alignment accuracy. Bioinformatics. 2021; 37(23):4572-4574. PMC: 8652018. DOI: 10.1093/bioinformatics/btab705. View

Rogier C, Pradines B, Bogreau H, Koeck J, Kamil M, Mercereau-Puijalon O . Malaria epidemic and drug resistance, Djibouti. Emerg Infect Dis. 2005; 11(2):317-21. PMC: 3320455. DOI: 10.3201/eid1102.040108. View

Danecek P, Bonfield J, Liddle J, Marshall J, Ohan V, Pollard M . Twelve years of SAMtools and BCFtools. Gigascience. 2021; 10(2). PMC: 7931819. DOI: 10.1093/gigascience/giab008. View

Snow R, Amratia P, Kabaria C, Noor A, Marsh K . The changing limits and incidence of malaria in Africa: 1939-2009. Adv Parasitol. 2012; 78:169-262. PMC: 3521063. DOI: 10.1016/B978-0-12-394303-3.00010-4. View

Amambua-Ngwa A, Amenga-Etego L, Kamau E, Amato R, Ghansah A, Golassa L . Major subpopulations of in sub-Saharan Africa. Science. 2019; 365(6455):813-816. DOI: 10.1126/science.aav5427. View

Mekonnen S, Aseffa A, Berhe N, Teklehaymanot T, Clouse R, Gebru T . Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia. Malar J. 2014; 13:244. PMC: 4230645. DOI: 10.1186/1475-2875-13-244. View

Warsame M, Hassan A, Barrette A, Jibril A, Elmi H, Arale A . Treatment of uncomplicated malaria with artesunate plus sulfadoxine-pyrimethamine is failing in Somalia: evidence from therapeutic efficacy studies and Pfdhfr and Pfdhps mutant alleles. Trop Med Int Health. 2015; 20(4):510-7. DOI: 10.1111/tmi.12458. View

Wang X, Ruan W, Zhou S, Huang F, Lu Q, Feng X . Molecular surveillance of Pfcrt and k13 propeller polymorphisms of imported Plasmodium falciparum cases to Zhejiang Province, China between 2016 and 2018. Malar J. 2020; 19(1):59. PMC: 7001319. DOI: 10.1186/s12936-020-3140-0. View

10.

Grossman T, Vainer J, Paran Y, Studentsky L, Manor U, Dzikowski R . Emergence of artemisinin-based combination treatment failure in patients returning from sub-Saharan Africa with P. falciparum malaria. J Travel Med. 2023; 30(8). DOI: 10.1093/jtm/taad114. View

11.

Noedl H, Se Y, Schaecher K, Smith B, Socheat D, Fukuda M . Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008; 359(24):2619-20. DOI: 10.1056/NEJMc0805011. View

12.

Moussa R, Papa Mze N, Arreh H, Abdillahi Hamoud A, Mohamed Alaleh K, Mohamed Aden F . Assessment of the Performance of Lactate Dehydrogenase-Based Rapid Diagnostic Test for Malaria in Djibouti in 2022-2023. Diagnostics (Basel). 2024; 14(3). PMC: 10854848. DOI: 10.3390/diagnostics14030262. View

13.

Moussa R, Papa Mze N, Arreh H, Abdillahi Hamoud A, Mohamed Alaleh K, Yonis Omar A . Molecular investigation of malaria-infected patients in Djibouti city (2018-2021). Malar J. 2023; 22(1):147. PMC: 10154177. DOI: 10.1186/s12936-023-04546-x. View

14.

Lucchi N, Komino F, Okoth S, Goldman I, Onyona P, Wiegand R . In Vitro and Molecular Surveillance for Antimalarial Drug Resistance in Plasmodium falciparum Parasites in Western Kenya Reveals Sustained Artemisinin Sensitivity and Increased Chloroquine Sensitivity. Antimicrob Agents Chemother. 2015; 59(12):7540-7. PMC: 4649220. DOI: 10.1128/AAC.01894-15. View

15.

Iriart X, Menard S, Chauvin P, Mohamed H, Charpentier E, Mohamed M . Misdiagnosis of imported malaria from African areas due to an increased prevalence of gene deletion: the Djibouti case. Emerg Microbes Infect. 2020; 9(1):1984-1987. PMC: 7534257. DOI: 10.1080/22221751.2020.1815590. View

16.

Warsame M, Hassan A, Hassan A, Arale A, Jibril A, Mohamud S . Efficacy of artesunate + sulphadoxine/pyrimethamine and artemether + lumefantrine and dhfr and dhps mutations in Somalia: evidence for updating the malaria treatment policy. Trop Med Int Health. 2017; 22(4):415-422. DOI: 10.1111/tmi.12847. View

17.

Harris E . Artemisinin Resistance Increasing. JAMA. 2023; 330(11):1030. DOI: 10.1001/jama.2023.16110. View

18.

Hassen J, Alemayehu G, Dinka H, Golassa L . High prevalence of Pfcrt 76T and Pfmdr1 N86 genotypes in malaria infected patients attending health facilities in East Shewa zone, Oromia Regional State, Ethiopia. Malar J. 2022; 21(1):286. PMC: 9547420. DOI: 10.1186/s12936-022-04304-5. View

19.

Rogier E, McCaffery J, Mohamed M, Herman C, Nace D, Daniels R . Plasmodium falciparum pfhrp2 and pfhrp3 Gene Deletions and Relatedness to Other Global Isolates, Djibouti, 2019-2020. Emerg Infect Dis. 2022; 28(10):2043-2050. PMC: 9514350. DOI: 10.3201/eid2810.220695. View

20.

Plowe C . Malaria chemoprevention and drug resistance: a review of the literature and policy implications. Malar J. 2022; 21(1):104. PMC: 8943514. DOI: 10.1186/s12936-022-04115-8. View